Non-Hodgkin's Lymphoma Clinical Trials

46 recruitingLast updated: June 18, 2026

There are 46 actively recruiting non-hodgkin's lymphoma clinical trials across 21 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3. Top locations include Beijing, Beijing Municipality, China, Hangzhou, Zhejiang, China, Beijing, China. Updated daily from ClinicalTrials.gov.


Non-Hodgkin's Lymphoma Trials at a Glance

46 actively recruiting trials for non-hodgkin's lymphoma are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 25 trials, with the heaviest enrollment activity in Beijing, Hangzhou, and Beijing. Lead sponsors running non-hodgkin's lymphoma studies include Chinese PLA General Hospital, Zhejiang University, and Baylor College of Medicine.

Browse non-hodgkin's lymphoma trials by phase

Treatments under study

About Non-Hodgkin's Lymphoma Clinical Trials

Looking for clinical trials for Non-Hodgkin's Lymphoma? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Hodgkin's Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Hodgkin's Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 2

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B Cell LymphomaNHLNon-Hodgkin's Lymphoma+1 more
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1

Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

Non-Hodgkin's Lymphoma
Chinese PLA General Hospital9 enrolled1 locationNCT07620314
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 2

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Follicular LymphomaLow Grade Non-Hodgkin's Lymphoma, Adult
Reid Merryman, MD100 enrolled6 locationsNCT05783609
Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Lymphoproliferative DisordersNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Dana-Farber Cancer Institute1,500 enrolled1 locationNCT00131014
Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 1Phase 2

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Non-Hodgkin's Lymphoma+1 more
City of Hope Medical Center15 enrolled1 locationNCT05801913
Recruiting
Phase 1

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

LymphomaNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Baylor College of Medicine136 enrolled3 locationsNCT01555892
Recruiting
Phase 1

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
AbbVie165 enrolled14 locationsNCT06667687
Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

Low Grade Non-Hodgkin's Lymphoma, Adult
Fondazione Italiana Linfomi - ETS150 enrolled20 locationsNCT05524298
Recruiting
Phase 1

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Baylor College of Medicine52 enrolled2 locationsNCT04664179
Recruiting
Phase 3

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Non-Hodgkin's LymphomaHematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University99 enrolled17 locationsNCT06520163
Recruiting

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

Acute Lymphoblastic LeukemiaLeukemiaNon-Hodgkin's Lymphoma
Goethe University10,000 enrolled152 locationsNCT02872987
Recruiting
Phase 1

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
PeproMene Bio, Inc.36 enrolled6 locationsNCT05370430
Recruiting
Phase 1

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Multiple MyelomaB Acute Lymphoblastic LeukemiaB-cell Non-Hodgkin's Lymphoma
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT07239323
Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Non-Hodgkin's LymphomaMycosis Fungoides
Stanford University2,000 enrolled13 locationsNCT02848274